famili
metalloproteas
repres
larg
number
exopeptidas
cleav
singl
amino
acid
residu
nterminu
peptid
substrat
one
member
famili
well
studi
aminopeptidas
n
apn
multifunct
proteas
known
cleav
biolog
activ
peptid
aid
coronaviru
entri
proteolyt
activ
apn
promot
cancer
angiogenesi
metastasi
make
import
target
cancer
therapi
understand
substrat
specif
apn
develop
target
inhibitor
use
global
substrat
profil
method
determin
amino
acid
prefer
key
structur
featur
apn
pharmacophor
requir
substrat
recognit
elucid
xray
crystallographi
combin
substrat
profil
structur
data
abl
design
select
peptid
inhibitor
apn
effect
therapeut
vitro
vivo
apnexpress
prostat
cancer
model
aminopeptidas
famili
group
zn
depend
peptidas
express
ubiquit
fetal
adult
tissu
protein
level
aminopeptidas
document
brain
pancrea
lung
intestin
prostat
heart
endotheli
cell
compon
immun
system
aminopeptidas
demonstr
uniqu
substrat
specif
prefer
certain
amino
acid
nterminu
endogen
substrat
exampl
aminopeptidas
b
prefer
basic
amino
acid
wherea
aminopeptidas
prefer
acid
amino
acid
substrat
specif
aminopeptidas
allow
select
catalyz
activ
metabol
bioactiv
peptid
studi
member
mammalian
aminopeptidas
famili
aminopeptidas
n
apn
also
known
apn
exist
dimer
kda
cell
surfac
protein
small
ntermin
intracellular
domain
singlepass
transmembran
anchor
small
extracellular
stalk
larg
ectodomain
cterminu
cleav
neutral
amino
acid
impli
n
name
apn
degrad
peptid
involv
differ
physiolog
pathway
includ
pain
sensat
mood
disord
inactiv
enkephalin
well
regul
blood
pressur
cleav
angiotensin
iii
apn
consid
moonlight
ectoenzym
possess
function
role
peptidas
independ
enzymat
activ
apn
also
act
receptor
viral
infect
adhes
molecul
cancer
apn
wide
overexpress
surfac
number
differ
cell
type
rang
endotheli
cell
solid
tumor
cell
enzymat
activ
apn
document
play
import
role
tumorigenesi
angiogenesi
cell
migrat
metastasi
result
role
cancer
develop
metastasi
apn
major
target
drug
develop
direct
enzymat
activ
apn
target
use
potent
transitionst
analogu
inhibitor
bestatin
ubenimex
sever
clinic
trial
although
bestatin
inhibit
nearli
dozen
aminopeptidas
demonstr
therapeut
benefit
acut
myeloid
leukemia
gastric
cancer
squamou
cell
lung
carcinoma
small
molecul
inhibitor
apn
includ
natur
product
curucumin
develop
undergo
test
clinic
preclin
model
bestatin
specif
plagu
nextgener
compound
due
limit
interact
small
molecul
make
apn
pharmacophor
addit
strategi
therapeut
target
apn
util
tumorhom
peptid
base
ngr
motif
bind
apn
deliv
cytotoxin
cancer
cell
one
agent
cyclic
version
ngr
peptid
complex
human
tumor
necrosi
factor
alpha
current
undergo
phase
iii
clinic
trial
mesothelioma
understand
substrat
specif
essenti
design
molecul
inhibit
enzymat
activ
apn
although
prefer
apn
neutral
amino
acid
residu
posit
gener
establish
littl
known
physic
basi
prefer
even
less
known
downstream
primesid
specif
apn
studi
perform
comprehens
evalu
apn
substrat
specif
identifi
key
structur
featur
dictat
specif
proteas
use
unbias
mass
spectrometrybas
peptid
librari
assay
determin
substrat
prefer
apn
priorit
candid
peptid
substrat
librari
ration
inhibitor
design
six
crystal
structur
apn
complex
differ
amino
acid
posit
solv
provid
structur
basi
substrat
specif
crystal
structur
peptid
model
specif
pocket
highlight
key
interact
respons
dictat
extend
primesid
substrat
specif
use
substrat
deriv
peptid
librari
develop
novel
substratebas
cyclic
peptid
inhibitor
specif
apn
inhibitor
specif
bound
apnexpress
prostat
cancer
cell
line
vitro
decreas
clonogen
surviv
effect
therapeut
lead
decreas
tumor
growth
vivo
xenograft
model
prostat
cancer
determin
substrat
specif
apn
recombin
human
apn
hapn
profil
use
unbias
global
substrat
profil
approach
refer
multiplex
substrat
profil
mass
spectrometri
mspm
mspm
assay
use
librari
synthet
unmodifi
peptid
substrat
ration
design
maxim
physicochem
divers
within
small
sequenc
space
specif
determin
hapn
incub
mspm
peptid
librari
timedepend
peptid
cleavag
product
identifi
liquid
chromatographi
tandem
mass
spectrometri
lcmsm
statist
analysi
consid
cleav
uncleav
posit
peptid
librari
subsequ
perform
construct
icelogo
represent
hapn
specif
well
correspond
heat
map
base
comprehens
zscore
posit
fig
b
supplement
figur
agreement
prior
specif
profil
use
singleamino
acid
fluorogen
substrat
hapn
display
broad
specif
posit
particular
hapn
exhibit
signific
prefer
hydrophob
residu
norleucin
leucin
tryptophan
alanin
wherea
prolin
asparagin
acid
residu
aspart
acid
glutam
acid
significantli
disfavor
note
norleucin
use
isoster
methionin
mspm
librari
inspect
individu
peptid
cleavag
event
within
mspm
time
cours
support
overarch
specif
prefer
ntermin
cleavag
impair
block
disfavor
residu
posit
fig
supplement
figur
shown
n
norleucin
residu
posit
percent
differ
consid
favor
given
posit
residu
neg
percent
differ
consid
disfavor
b
heat
map
represent
hapn
specif
min
assay
time
point
calcul
use
zscore
posit
favor
residu
color
blue
zscore
disfavor
residu
color
red
zscore
icelogo
represent
heat
map
min
assay
time
point
provid
supplementari
figur
c
exampl
peptid
mspm
librari
shown
primari
secondari
cleavag
indic
blue
arrow
x
indic
cleavag
detect
indic
posit
progress
curv
provid
depict
total
cleavag
observ
assay
time
point
scientif
report
addit
provid
specif
hapn
global
analysi
reveal
numer
nonprimesid
specif
featur
particular
featur
includ
among
other
signific
prefer
certain
hydrophob
residu
tryptophan
phenylalanin
prolin
posit
prefer
serinethreonin
phenylalanin
posit
decreas
prefer
prolin
posit
fig
b
supplement
figur
structur
basi
apn
substrat
specif
provid
molecular
basi
apn
substrat
recognit
catalysi
crystal
structur
solv
apn
bound
natur
free
amino
acid
vari
prefer
methionin
leucin
arginin
glycin
isoleucin
aspart
acid
probe
influenc
extend
bind
pocket
due
nearli
ident
architectur
activ
site
specif
papn
hapn
papn
use
analysi
propens
form
high
qualiti
crystal
crystal
structur
papn
complex
free
amino
acid
alanin
seven
amino
acid
polyalanin
peptid
substrat
initi
determin
figur
seahorseshap
ectodomain
papn
contain
domain
head
side
bodi
tail
fig
ntermin
residu
peptid
substrat
firmli
anchor
spaciou
activ
site
apn
head
bodi
domain
residu
form
hydrogen
bond
free
ntermin
amin
group
fig
c
nitrogen
scissil
peptid
bond
form
hydrogen
bond
electronrepel
carbonyl
oxygen
carbonyl
oxygen
scissil
peptid
bond
interact
electronattract
zinc
fig
c
reson
electron
scissil
peptid
bond
pull
toward
carbonyl
oxygen
thu
destabil
bond
make
avail
nucleophil
attack
zincactiv
water
molecul
time
activ
nitrogen
scissil
peptid
bond
also
readi
accept
proton
catalyt
water
side
chain
presenc
free
alanin
carbonyl
oxygen
papn
maintain
hydrogen
bond
carboxyl
group
free
alanin
suggest
carboxyl
group
oxygen
free
alanin
near
proton
proton
carboxyl
group
oxygen
free
alanin
due
simultan
deproton
carboxyl
group
oxygen
free
alanin
zinc
fig
e
papn
form
interact
free
alanin
ntermin
alanin
residu
polyalanin
peptid
substrat
believ
crystal
structur
papn
complex
free
amino
acid
reflect
interact
papn
ntermin
amino
acid
residu
least
simpl
peptid
substrat
free
amino
acid
crystal
structur
bound
papn
similar
manner
alanin
except
key
differ
side
chain
interact
amino
acid
side
chain
orient
pocket
papn
bodi
domain
hydrophob
wall
open
end
fig
side
chain
differ
length
abl
fit
pocket
open
end
found
primarili
form
hydrophob
interact
wall
pocket
fig
exampl
c
c
c
methionin
side
chain
form
hydrophob
interact
pocket
wall
fig
polar
side
chain
also
abl
form
addit
interact
papn
case
arginin
guanidin
group
form
cationicpi
interact
fig
gener
apnbind
affin
amino
acid
posit
associ
extent
hydrophob
affinityincreas
interact
side
chain
pocket
wall
consequ
amino
acid
long
nonpolar
side
chain
like
leucin
gener
high
apnbind
affin
analysi
crystal
structur
papn
complex
nonfavor
amino
acid
found
residu
share
one
uniqu
featur
side
chain
unfavor
interact
catalyt
critic
carbonyl
oxygen
papn
fig
exampl
c
atom
isoleucin
away
carbonyl
oxygen
respect
fig
short
distanc
strong
van
der
waal
vdw
repuls
exist
atom
addit
group
aspart
acid
form
unfavor
charg
repuls
carbonyl
oxygen
fig
comparison
side
chain
disfavor
ile
asp
residu
apn
papn
residu
magenta
amino
acid
green
catalyt
critic
hydrogen
bond
carbonyl
oxygen
ctermin
carboxyl
group
amino
acid
shown
red
dash
line
structur
ala
omit
panel
clariti
interact
carbonyl
oxygen
amino
acid
side
chain
shown
black
dash
line
distanc
carbonyl
oxygen
nearest
atom
amino
acid
side
chain
shown
bidirect
arrow
scientif
report
amino
acid
good
apn
substrat
form
weak
interact
carbonyl
oxygen
fig
identifi
sequenc
inhibitor
develop
select
peptid
mspm
librari
underw
complet
hydrolysi
assay
compar
use
labelfre
quantit
peptid
cleavag
kinet
supplement
figur
fiveresidu
long
peptid
contain
residu
primari
cleavag
librari
synthes
test
abil
prevent
cleavag
fluorogen
alanin
substrat
hapn
initi
peptid
nhspw
abl
appreci
inhibit
substrat
cleavag
ic
wherea
remain
peptid
ic
valu
tabl
replac
residu
norleucin
nhspw
either
leucin
alanin
signific
impact
ic
result
low
inhibitor
complet
remov
norleucin
result
peptid
hspw
decreas
potenc
inhibitor
defin
key
primesid
interact
account
inhibit
hspwcontain
sequenc
peptid
lhspw
model
papn
crystal
structur
fig
model
purpos
residu
select
leucin
sinc
solv
crystal
structur
residu
posit
unabl
get
crystal
structur
norleucin
leucin
second
favor
residu
mspm
assay
first
three
residu
model
polyalanin
structur
last
two
residu
structur
papn
complex
substanc
p
also
contain
prolin
posit
pdb
id
predict
structur
data
side
chain
peptid
point
hydrophob
pocket
surround
apn
residu
fig
side
chain
form
hydrogen
bond
main
chain
carbonyl
oxygen
papn
residu
form
turn
peptid
wherea
side
chain
form
vdw
interact
apn
residu
fig
use
hspw
core
sequenc
next
sought
creat
true
inhibitor
apn
cleavabl
substrat
potenti
proteolyt
stabil
requir
vivo
studi
addit
ntermin
cap
group
peptid
complet
abrog
inhibitori
abil
next
peptid
cycliz
format
disulfid
bond
use
n
ctermin
cystein
residu
cysxhspwci
cycxhspw
cycliz
parent
nhspw
peptid
cystein
residu
cycnhspw
also
elimin
measur
inhibit
apn
howev
cycliz
leucin
deriv
cyclhspw
yield
inhibitor
k
truncat
core
sequenc
reveal
import
determin
affin
cyclic
peptid
result
k
valu
cyclic
tetrapeptid
tripeptid
deriv
respect
biolog
evalu
cyclhspw
next
specif
lead
peptid
inhibitor
cyclhspw
test
panel
cancerassoci
proteas
widerang
substrat
specif
fig
apn
proteas
inhibit
cyclhspw
chymotrypsin
trypsin
psa
aminopeptidas
exopeptidas
fap
k
valu
assess
select
purifi
epkva
apn
next
evalu
abil
cyclhspw
preferenti
bind
cell
express
surfac
apn
use
flow
cytometri
fig
flow
cytometri
synthes
fluorophorecontain
version
peptid
possess
gli
fitc
group
coupl
ctermin
cystein
supplement
figur
express
cell
surfaceassoci
apn
examin
androgen
receptor
neg
neuroendocrin
prostat
cancer
cell
line
use
commerci
avail
antibodi
cell
line
found
express
surfaceassoci
apn
wherea
detect
express
found
cell
line
method
incub
cell
line
fitc
label
cyclhspw
peptid
preferenti
bound
cell
notic
label
cell
peptid
next
test
frozen
tumor
xenograft
section
preferenti
label
xenograft
section
evid
further
attest
specif
cyclhspw
fluoresc
microscopi
potenti
therapeut
efficaci
cyclhspw
next
test
vitro
use
cell
line
apn
inhibitor
demonstr
specif
pronounc
therapeut
benefit
result
decreas
clonal
surviv
cell
signific
biolog
effect
observ
either
cell
line
treatment
hydrolyz
lhspw
peptid
cycnhspw
deriv
prior
vivo
therapeut
efficaci
studi
toxic
studi
perform
iv
administr
cyclhspw
found
singl
high
dose
mg
kg
well
toler
mice
howev
multipl
dose
concentr
would
need
result
cachexia
found
dose
mgkg
administ
three
time
week
four
week
tiw
well
toler
ie
sign
morbid
mice
bear
establish
xenograft
treat
system
via
tail
vein
inject
mgkg
tumor
home
apn
peptid
cycngr
cyclhspw
peptid
tiw
fig
inhibit
tumor
growth
xenograft
mice
treat
cyclhspw
signific
p
three
week
trial
compar
salineand
cycngrtreat
arm
therapeut
effect
persist
end
studi
cyclhspwtreat
mice
tumor
volum
mm
day
littl
therapeut
effect
observ
cycngrtreat
mice
salineand
cycngrtreat
arm
tumor
volum
mm
end
studi
tumor
remov
stain
cellular
prolifer
marker
salineand
cycngrtreat
tumor
profoundli
higher
popul
k
posit
cell
compar
cyclhspwtreat
tumor
fig
therapeut
effect
observ
apnneg
tumor
treat
either
cyclhspw
cycngr
proteas
respons
increas
proteolysi
associ
aggress
form
cancer
repres
candid
therapeut
target
overexpress
apn
surfac
neovasculatur
solid
tumor
made
studi
member
famili
metalloproteas
target
number
group
develop
molecul
target
apn
rang
monoclon
antibodi
synthet
peptidomimet
inhibitor
enzymat
activ
perhap
wellknown
apn
cyclic
tumorhom
peptid
asparagineglycinearginin
cycngr
origin
discov
vivo
peptid
phage
display
peptid
radiolabel
nuclear
imag
use
deliv
therapeut
peptid
protein
vivo
apnexpress
tissu
ngr
motif
mimic
structur
extracellular
matrix
protein
apn
known
bind
degrad
number
drawback
associ
use
cycngr
peptid
foremost
among
deamid
asparagin
residu
spontan
reaction
enhanc
asparagin
adjac
glycin
residu
result
format
isoaspartateglycinearginin
isodgr
ligand
capabl
bind
v
integrin
sever
integrin
lower
affin
deamid
lead
decreas
specif
potenti
target
affect
addit
demonstr
studi
cyclicngr
peptid
alon
therapeut
rather
therapeut
conjug
toxin
thu
great
need
lowmolecular
weight
apntarget
therapeut
stabl
specif
develop
target
agent
apn
greatli
hinder
two
factor
incomplet
understand
apn
substrat
specif
recent
pauciti
highresolut
atom
structur
present
comprehens
examin
substrat
specif
apn
date
detail
key
structur
interact
dictat
specif
understand
molecular
architectur
apn
atom
level
invest
specif
global
profil
techniqu
abl
ration
design
peptid
inhibitor
enzymat
activ
pocket
apn
hydrophob
wall
open
end
result
presenc
predict
architectur
specif
apn
favor
hydrophob
residu
amino
acid
larg
posit
charg
side
chain
arginin
lysin
also
toler
substrat
side
chain
form
hydrophob
polar
interact
aforement
residu
pocket
contrast
acid
residu
glutam
acid
aspart
acid
shortbranch
residu
asparagin
prolin
strongli
disfavor
posit
due
charg
vdw
repuls
respect
activ
site
apn
expans
open
three
side
allow
accommod
larg
peptid
substrat
exclus
monoaminopeptidas
activ
direct
result
hydrogen
bond
form
activ
site
residu
ntermin
amin
group
peptid
substrat
diaminopeptidas
activ
observ
favor
hydrogen
bond
made
anchor
peptid
proper
orient
bond
hydrolysi
import
hydrogen
bond
peptid
bind
also
evid
inhibitor
studi
ntermini
hspw
peptid
cap
differ
group
remov
one
potenti
hydrogen
bond
nterminu
cap
peptid
unabl
bind
result
poor
inhibit
addit
residu
global
analysi
reveal
previous
uncharacter
primesid
specif
featur
dictat
hydrophob
interact
addit
hydrogen
bond
main
chain
group
import
interact
evid
hspw
core
sequenc
lead
inhibitor
truncat
remov
abrog
abil
peptid
inhibit
apn
critic
interact
two
residu
make
activ
site
observ
model
experi
document
residu
form
vdw
interact
end
result
studi
cyclic
peptid
cyclhspw
potent
specif
inhibitor
apn
inhibit
enzymat
activ
apn
found
cyclhspw
therapeut
vitro
vivo
model
highli
aggress
neuroendocrin
prostat
cancer
aggress
form
cancer
rise
highli
plausibl
futur
treatment
neuroendocrin
prostat
cancer
could
involv
target
apn
investig
substrat
specif
apn
underscor
util
mspm
assay
convent
techniqu
determin
aminopeptidas
specif
number
limit
exist
use
singleamino
acid
chromogen
fluorogen
substrat
determin
aminopeptidas
specif
report
group
exampl
potenti
alter
specif
profil
addit
report
primesid
specif
global
approach
also
allow
identif
individu
synthet
peptid
bona
fide
substrat
serv
templat
apn
inhibitor
design
apn
emerg
import
pericellular
proteas
target
aggress
cancer
envis
substrat
specif
prefer
identifi
guid
develop
nextgener
apntarget
therapeut
well
aid
discoveri
endogen
substrat
expand
knowledg
role
biolog
apn
express
purif
porcin
apn
ectodomain
residu
human
apn
ecdomain
residu
express
purifi
previous
describ
briefli
apn
ectodomain
contain
ntermin
honeybeemelittin
signal
peptid
ctermin
tag
express
insect
cell
secret
cell
cultur
medium
purifi
sequenti
ninta
column
gelfiltr
column
mspm
assay
carri
describ
previous
briefli
recombin
human
apn
r
system
catalog
match
noenzym
control
assay
divers
librari
tetradecapeptid
pool
nm
dpb
ph
contain
mm
tcep
min
assay
mixtur
remov
quench
formic
acid
flashfrozen
liquid
n
prior
mass
spectrometri
acquisit
peptid
sampl
desalt
use
c
desalt
tip
rehydr
formic
acid
lcm
ms
data
acquir
use
thermo
scientif
ltqft
mass
spectromet
equip
thermo
scientif
easyspray
ion
sourc
easyspray
pepmap
c
column
water
nanoacqu
uplc
system
peptid
peak
list
gener
use
msconvert
proteowizard
toolkit
data
search
peptid
librari
use
protein
prospector
softwar
univers
california
san
francisco
protein
prospector
score
threshold
select
minimum
protein
score
minimum
peptid
score
maximum
expect
valu
use
protein
peptid
match
respect
substrat
specif
profil
gener
icelogo
softwar
use
possibl
cleavag
mspm
librari
n
neg
data
set
describ
extract
ion
chromatogram
labelfre
quantit
select
substrat
product
speci
gener
use
skylin
softwar
univers
washington
specif
constant
k
cat
k
calcul
describ
raw
spectrum
raw
file
mspm
experi
studi
avail
proteosaf
resourc
ftp
massiveucsdedu
usernam
password
hapn
porcin
apn
ectodomain
crystal
previous
describ
briefli
papn
mgml
concentr
buffer
contain
mm
tri
mm
nacl
crystal
amino
acid
soak
papn
crystal
crystal
papn
set
protein
solut
well
solut
contain
mm
li
mm
hepe
mix
togeth
sit
drop
crystal
papn
grown
two
week
transfer
amino
acidsoak
solut
contain
mm
amino
acid
ethylen
glycol
mm
li
mm
hepe
anoth
two
day
crystal
flash
frozen
liquid
use
data
collect
data
collect
ap
beamlin
al
beamlin
xray
diffract
data
process
use
structur
papn
complex
differ
amino
acid
determin
directli
refin
model
unligand
papn
structur
pdb
amino
acidsoak
crystal
data
program
cn
refmac
use
structur
refin
program
coot
use
model
build
structur
superposit
six
amino
acid
soak
papn
crystal
determin
structur
papnamino
acid
complex
structur
unligand
papn
use
determin
structur
amino
acidsoak
papn
object
fofc
omit
map
calcul
absenc
amino
acid
show
strong
electron
densiti
amino
acid
supplement
figur
base
map
model
amino
acid
built
model
papnamino
acid
complex
refin
crystallograph
statist
found
supplement
figur
peptid
synthesi
inhibitor
test
peptid
use
studi
custom
synthes
aapptec
louisvil
ky
use
tradit
fmoc
solidphas
peptid
synthesi
peptid
purifi
character
aapptec
peptid
use
studi
greater
puriti
determin
highperform
liquid
chromatographi
inhibit
assay
perform
triplic
mm
tri
ph
brij
wv
assay
buffer
apn
halaamc
fluorophor
valu
record
infinit
pro
plate
reader
everi
minut
minut
laser
paramet
set
excit
nm
emiss
nm
inhibit
apn
competit
valu
inhibit
constant
k
determin
use
chengprusoff
equat
k
ic
km
flow
cytometri
microscopi
cell
wash
pb
harvest
mechan
cell
scraper
total
cell
incub
nmoll
cyclhspw
gli
fitc
antibodi
miltenyi
minut
stain
sampl
control
assay
bd
facscalibur
tumor
section
frozen
oct
medium
section
thick
briefli
fix
cold
aceton
min
rins
pb
section
stain
nm
cyclhspw
gli
fitc
overnight
section
wash
pb
mount
dapi
prolong
gold
slide
visual
use
nikon
high
throughput
epifluoresc
microscop
vitro
vivo
therapeut
studi
clonogen
surviv
assay
conduct
previous
describ
mous
care
treatment
approv
perform
accord
guidelin
univers
minnesota
institut
anim
care
use
committe
cell
maintain
standard
condit
detach
treatment
trypsinedta
solut
wash
hank
balanc
salt
solut
hbss
suspend
mixtur
matrigel
matrix
bd
bioscienc
hbss
concentr
cell
per
solut
cell
inject
subcuti
overli
rear
flank
male
nude
mice
harlan
tumor
establish
anim
random
three
treatment
group
per
xenograft
cyclhspw
cycngr
dissolv
dmso
dilut
steril
pb
final
dmso
concentr
vv
mice
dose
via
tail
vein
inject
mgkg
cyclic
peptid
salin
day
three
time
week
four
week
total
tumor
measur
made
twice
weekli
calip
tumor
volum
mm
calcul
formula
length
l
width
w
height
h
endpoint
studi
either
five
week
first
treatment
dose
tumor
reach
volum
mm
dictat
anim
protocol
tumor
remov
euthan
anim
formalin
fix
stain
use
manufactur
protocol
statist
analysi
data
analyz
use
unpair
twotail
student
test
differ
confid
level
p
consid
statist
signific
